HUE038511T2 - (1,4)-N-acetil-galaktóz-aminil-transzferáz vagy (1,4)-N-acetil-galaktóz-aminil-transzferázból származó glikoziltranszferázt alkalmazó, glikoprotein módosítására szolgáló eljárás - Google Patents

(1,4)-N-acetil-galaktóz-aminil-transzferáz vagy (1,4)-N-acetil-galaktóz-aminil-transzferázból származó glikoziltranszferázt alkalmazó, glikoprotein módosítására szolgáló eljárás

Info

Publication number
HUE038511T2
HUE038511T2 HUE16722547A HUE16722547A HUE038511T2 HU E038511 T2 HUE038511 T2 HU E038511T2 HU E16722547 A HUE16722547 A HU E16722547A HU E16722547 A HUE16722547 A HU E16722547A HU E038511 T2 HUE038511 T2 HU E038511T2
Authority
HU
Hungary
Prior art keywords
acetylgalactosaminyltransferase
glycosyltransferase
glycoprotein
derived
modification
Prior art date
Application number
HUE16722547A
Other languages
English (en)
Inventor
Berkel Sander Sebastiaan Van
Geel Remon Van
Maria Antonia Wijdeven
Delft Floris Louis Van
Original Assignee
Synaffix Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synaffix Bv filed Critical Synaffix Bv
Publication of HUE038511T2 publication Critical patent/HUE038511T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01038—Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase (2.4.1.38)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01092—(N-acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosaminyltransferase (2.4.1.92)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HUE16722547A 2015-04-23 2016-04-25 (1,4)-N-acetil-galaktóz-aminil-transzferáz vagy (1,4)-N-acetil-galaktóz-aminil-transzferázból származó glikoziltranszferázt alkalmazó, glikoprotein módosítására szolgáló eljárás HUE038511T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15164864 2015-04-23

Publications (1)

Publication Number Publication Date
HUE038511T2 true HUE038511T2 (hu) 2018-10-29

Family

ID=52997984

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16722547A HUE038511T2 (hu) 2015-04-23 2016-04-25 (1,4)-N-acetil-galaktóz-aminil-transzferáz vagy (1,4)-N-acetil-galaktóz-aminil-transzferázból származó glikoziltranszferázt alkalmazó, glikoprotein módosítására szolgáló eljárás

Country Status (12)

Country Link
US (3) US9988661B2 (hu)
EP (2) EP3354726A1 (hu)
JP (1) JP6966162B2 (hu)
CN (2) CN115960981A (hu)
DK (1) DK3134520T3 (hu)
ES (1) ES2659816T3 (hu)
HR (1) HRP20180439T1 (hu)
HU (1) HUE038511T2 (hu)
NO (1) NO3134520T3 (hu)
PL (1) PL3134520T3 (hu)
PT (1) PT3134520T (hu)
WO (1) WO2016170186A1 (hu)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2623609B1 (en) 2006-02-10 2017-01-04 Life Technologies Corporation Labeling and detection of post translationally modified proteins
KR20170030648A (ko) 2014-08-04 2017-03-17 시나픽스 비.브이. 베타-(1,4)-n-아세틸갈락토오스아미닐트랜스퍼라아제, 또는 이의 돌연변이체를 이용한 당 단백질의 변형 방법
NO3134520T3 (hu) 2015-04-23 2018-05-19
JP2019507741A (ja) 2016-02-08 2019-03-22 シンアフィックス ビー．ブイ． 治療において使用するためのスルファミドリンカーを含むバイオコンジュゲート
CN108883191B (zh) 2016-02-08 2022-10-14 西纳福克斯股份有限公司 用于靶向cd30肿瘤的具有改善的治疗指数的抗体-缀合物以及用于改善抗体-缀合物的治疗指数的方法
WO2017137457A1 (en) 2016-02-08 2017-08-17 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
WO2017137423A1 (en) 2016-02-08 2017-08-17 Synaffix B.V. Improved sulfamide linkers for use in bioconjugates
EP3413915A1 (en) 2016-02-08 2018-12-19 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting her2 tumours and method for improving therapeutic index of antibody-conjugates
WO2019110725A1 (en) 2017-12-06 2019-06-13 Synaffix B.V. Enediyne conjugates
JP2021528406A (ja) 2018-06-19 2021-10-21 グリコス バイオメディカル オーワイ コンジュゲート
AU2019293857A1 (en) 2018-06-29 2020-12-10 Glykos Finland Oy Conjugates
MX2021001284A (es) 2018-08-02 2021-07-15 Dyne Therapeutics Inc Complejos dirigidos al musculo y sus usos para el tratamiento de distrofia muscular facioescapulohumeral.
CN112955153A (zh) 2018-08-02 2021-06-11 达因疗法公司 肌肉靶向复合物及其用于治疗肌养蛋白病的用途
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP3876998A1 (en) 2018-11-05 2021-09-15 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
CN110195043A (zh) * 2019-05-15 2019-09-03 武汉格莱利生物科技有限公司 一种高水溶性的cgta酶及其制备方法和应用
WO2020245229A1 (en) 2019-06-03 2020-12-10 Synaffix B.V. Acetal-based cleavable linkers
NL2023572B1 (en) * 2019-07-25 2021-02-10 Synaffix Bv Synthesis of 6-azido-6-deoxy-2-N-acetyl-hexosamine-nucleoside diphosphate
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate
TW202140075A (zh) 2020-01-09 2021-11-01 美商梅爾莎納醫療公司 具有含肽之連接子的位置特異性抗體－藥物共軛體
CN115666656A (zh) 2020-01-13 2023-01-31 西纳福克斯股份有限公司 通过环加成双侧功能化抗体
EP4090377A1 (en) 2020-01-13 2022-11-23 Synaffix B.V. Conjugates of antibodies an immune cell engagers
CN115243727A (zh) 2020-01-13 2022-10-25 西纳福克斯股份有限公司 经由环加成的双侧官能化抗体
NL2026400B1 (en) 2020-09-02 2022-05-04 Synaffix Bv Methods for the preparation of bioconjugates
WO2022058395A1 (en) 2020-09-15 2022-03-24 Synaffix B.V. Antibody-exatecan conjugates
NL2026947B1 (en) 2020-11-20 2022-07-01 Synaffix Bv Tyrosine-based antibody conjugates
EP4267195A1 (en) 2020-12-24 2023-11-01 Synaffix B.V. Glycan-conjugated antibodies binding to fc-gamma receptor
US11964024B2 (en) * 2021-01-04 2024-04-23 Mersana Therapeutics, Inc. B7H4-targeted antibody-drug conjugates and methods of use thereof
CN117157107A (zh) 2021-02-08 2023-12-01 西纳福克斯股份有限公司 多功能抗体
WO2022187591A1 (en) 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
CA3228178A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
WO2023161296A1 (en) 2022-02-22 2023-08-31 Adc Therapeutics Sa Conjugation method involving a transglutaminase at the fc region comprising a trimmed n-glycan
IL315207A (en) 2022-03-23 2024-10-01 Synaffix B V Antibody pairs for targeting TROP-2 expressing tumors
WO2023180490A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing nectin-4
WO2023180489A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
AU2023237619A1 (en) 2022-03-23 2024-08-29 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing ptk7
AU2023254846A1 (en) 2022-04-15 2024-10-10 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
EP4285934A1 (en) 2022-05-30 2023-12-06 CER Groupe Modified trimannose-oligosacharides, bisected n-glycans comprising said trimannose core and method for obtaining them
WO2024038065A1 (en) 2022-08-15 2024-02-22 Synaffix B.V. Anthracyclins and conjugates thereof
EP4389152A1 (en) 2022-12-23 2024-06-26 Synaffix B.V. Conjugates of pbd prodrugs
EP4410313A1 (en) 2023-01-31 2024-08-07 Synaffix B.V. Homogeneous antibody-conjugates with high payload loading

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030066748A (ko) * 2000-12-21 2003-08-09 교와 핫꼬 고교 가부시끼가이샤 Ｕｄｐ-ｎ-아세틸갈락토사민 및 ｎ-아세틸갈락토사민 함유사카라이드의 제조법
FI20011671A (fi) 2001-08-20 2003-02-21 Carbion Oy Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
WO2004024938A2 (en) * 2002-09-13 2004-03-25 Cummings Richard D Β1,4-n-acetylgalactosaminyltransferases, nucleic acids and methods of use thereof
JP2008514215A (ja) 2004-09-29 2008-05-08 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 改変タンパク質
EP2623609B1 (en) 2006-02-10 2017-01-04 Life Technologies Corporation Labeling and detection of post translationally modified proteins
AR076555A1 (es) * 2009-05-11 2011-06-22 Stichting Tech Wetenschapp Antigeno glicano. uso. anticuerpo. vacuna. metodo para fabricar vacuna
CN101575631B (zh) * 2009-05-15 2011-11-16 南开大学 一种半乳糖基转移酶修饰黄酮类糖苷化合物的方法
CN102313801A (zh) * 2011-06-03 2012-01-11 南开大学 一种抗体的代谢标记方法及其荧光检测中的应用
GB201115841D0 (en) 2011-09-13 2011-10-26 Genovis Ab Protein and method
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
US10266502B2 (en) 2014-01-24 2019-04-23 Synaffix B.V. Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
CN112494657A (zh) 2014-10-03 2021-03-16 西纳福克斯股份有限公司 磺酰胺接头、其缀合物及制备方法
NO3134520T3 (hu) * 2015-04-23 2018-05-19

Also Published As

Publication number Publication date
JP6966162B2 (ja) 2021-11-10
NO3134520T3 (hu) 2018-05-19
US12049656B2 (en) 2024-07-30
CN107810273A (zh) 2018-03-16
PT3134520T (pt) 2018-03-26
CN107810273B (zh) 2022-09-27
WO2016170186A1 (en) 2016-10-27
EP3134520B1 (en) 2017-12-20
PL3134520T3 (pl) 2018-06-29
ES2659816T3 (es) 2018-03-19
US20180245119A1 (en) 2018-08-30
JP2018518149A (ja) 2018-07-12
EP3134520A1 (en) 2017-03-01
DK3134520T3 (en) 2018-03-19
CN115960981A (zh) 2023-04-14
HRP20180439T1 (hr) 2018-07-13
US20230100074A1 (en) 2023-03-30
US9988661B2 (en) 2018-06-05
EP3354726A1 (en) 2018-08-01
US11299759B2 (en) 2022-04-12
US20170130256A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
HRP20180439T1 (hr) Postupak modificiranja glikoproteina glikoziltransferazom koja je ili je derivat beta-(1,4)-n-acetilgalaktozaminil transferaze
ZA202006002B (en) Process for manipulating the level of glycan content of a glycoprotein
HUE064642T2 (hu) Eljárás ozanimod elõállítására
ZA201902125B (en) Process for the production of 2-alkylalkanol
PL3230236T3 (pl) Sposób wytwarzania 1,3-butadienu z 1,3-butanodiolu
ZA201801820B (en) A process of controlling the morphology of graphite
ZA201704983B (en) Process for the preparation of microcapsules free from melamine-formaldehyde
SI3160985T1 (sl) Postopek za pripravo D-arginil-2,6-dimetil-L-tirosil-L-lisil-L- fenilalaninamida
IL262941B (en) A particle for genome engineering system encapsidation
MX2017011389A (es) Proceso para la preparacion de 3-cloro-2-vinilfenilsulfonatos.
PL3286373T3 (pl) Sposoby wytwarzania nanocelulozy o wysokiej zawartości substancji stałych
PL3330244T3 (pl) Sposób produkcji 2,3,3,3-tetrafluoropropenu
IL275381A (en) A process for the preparation of Crisborole
SI3592723T1 (sl) Postopek za pripravo 3,3,3-trifluoroprop-1-ene
GB2561089B (en) Process for the preparation of 17beta-hydroxy-des-a-androst-9, 10-en-5-one
MX2016017019A (es) Metodo para la preparacion de 4-alcoxi-1,1,1-trifluorobut-3-en-2-o nas de 1,1,1 trifluoroacetona.
MX2016016398A (es) Preparacion de piperidin-4-carbotioamida.
PL3489218T3 (pl) Sposób wytwarzania fenyloaminohydroksyantrachinonów
EP3256131A4 (en) 3,5-DIHYDROXYPENTANOATE ANALOGUES FOR BONE FORMATION
GB201717809D0 (en) Process for the production of cobimetinib
MX2017011388A (es) Proceso para la preparacion de derivados de fenilisoxazolina sustituida.